Carasent AB (CARA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to our presentation of the first quarter of 2025. My name is Daniel Erman and I will start to present and then I will hand over to Martin Björstedt, our CFO, to take the rest of the presentation. So looking at the first quarter, we continue to improve rapidly. We have our EBITDA margin going from minus 8% to plus 6%. And that's our most important financial metrics internally. And performance is in line with our plan overall. We have slightly higher costs in the quarter than we had planned for. And it's not a lot we're talking about. We're talking about 1 to 2 million more costs than we would have liked to have. So it's not a big deviation. And this deviation is due to partly that we have chosen to invest more into AI. And then we're talking AI in our products, AI in our development. We've been working with it for a long time. We've been able to offset most of the costs of development in AI by getting rid of other costs, but some of it has increased our total costs. We also had to do some write-down of the receivables from the companies that went bankrupt as we spoke about in the last quarter. We also have had discussions in the board about capital allocation and I will get back to that later on in the presentation. feel that we have good progress in our large development projects that's surgery for sweden e-prescription there's a new regulation around e-prescription called nll in sweden which means that in all ehr systems you will be able to see all prescriptions from all other systems and you will also be able to change those prescriptions so that would be a really good thing for our customers that even if you're not in in one of the regional systems you will still be able to see all everything around medication and that way around also. Vol...